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capillary action until immobilized by anti-Cryptococcal
antibodies at the test line, thereby resulting a visible
positive test [9].
LFA is also useful for quantification of CrAg by titration
apart from the diagnostic (qualitative) purpose, which is
clinically important to predict the risk of death and
immune reconstitution syndrome [10,11]. LFA employs
different dilution steps for qualitative (1 : 2) versus semi-
quantitative titration (1 : 5, 1 : 10, 1 : 20, 1 : 40, 1 : 80,
1 : 160 and so on).
In conclusion, when there is high suspicion of
cryptococcal meningitis in the setting of a negative
CSF CrAg LFA, a serial dilution (i.e. semi-quantitative
titration) must be performed to rule out a false-negative
test due to the postzone phenomenon.
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Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir
and cobicistat
With great interest we read the article by Antonio et al. [1]
reporting on the serological response to syphilis treatment
with penicillin benzathine or doxycycline in patients with
HIV following a manufacturing shortfall of penicillin
benzathine. No differences in serological response were
observed between the two treatment strategies. Long-acting
penicillin formulations, however, remainfirst-line treatment
for syphilis [2]. Dependent on the stage of the infection,
treatment is recommended by a single injection of 2.4
million units benzylpenicillin benzathine [early infection
(acquired within the last 12 months)] or by three successive
weekly injections of 2.4 million units (late infection).
Administration of benzylpenicillin benzathine is recom-
mended to be split over two doses of 1.2 million units, each
in one buttock [3]. Discomfort of these injections can be
reduced by replacing part of the solvent by a lidocaine
(lignocaine) solution [3]. In addition to manufacturing
shortfalls, treatment with benzylpenicillin benzathine may
be complicated by drug–drug interactions between
lidocaine and components of HIV treatment regimens,
especially with inhibitors of lidocaine metabolism.
Lidocaine is metabolized in the liver by cytochrome P450
3A4 (CYP3A4) to its metabolite monoethylglyxinexylidide
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(MEGX) [4]. To enhance exposure to antiretroviral
drugs, such as atazanavir, darunavir and elvitegravir,
ritonavir and cobicistat are used as boosters in combined
antiretroviral therapy. Ritonavir and cobicistat inhibit
CYP3A4, resulting in an increased exposure (increased
area under the curve), increased maximum concentration
(Cmax) and increased half-life (t1/2) of antiretroviral drugs
that are substrates of CYP3A4 [5]. Drug–drug interac-
tions between ritonavir or cobicistat and lidocaine have
been suggested to increase lidocaine exposure by more
than three-fold [6], complicating treatment with ben-
zylpenicillin benzathine as this interaction may lead to
higher plasma lidocaine levels and adverse effects,
including neurological and cardiac side effects. Neuro-
logical side effects may consist of respiratory depression,
convulsion and coma. Cardiac effects may include
elevated blood pressure, increased heart rate (HR) and
cardiac output with mild intoxications and, with severe
intoxications, reduced HR, conduction velocity and
contraction of the heart with dilated vessels [7]. The
clinical relevance of the interaction between ritonavir and
cobicistat and lidocaine during the treatment of syphilis in
HIV patients has not been reported thus far.
To determine the relevance of this interaction, lidocaine
peak serum levels were determined in three male HIV-
positive patients suspect for syphilis infection (refer to
Table 1 for details on the patients). Patients were treated
with two injections of 1.2 million units benzylpenicillin
benzathine dissolved in 2 ml of water for injection and 2
ml of lidocaine 20 mg/ml, according to local guidelines.
In total 80 mg of lidocaine was administered by
intramuscular injection. Peak concentrations for lido-
caine are expected about 30–60 min after intramuscular
administration [8]. Lidocaine serum levels were deter-
mined with a validated liquid chromatography–tandem
mass spectrometry method. Lidocaine peak serum levels
were found to range from 0.2 to 0.6 mg/l (Table 1).
Therapeutic lidocaine levels for the treatment of
arrhythmia are in the range 1.5–6 mg/l [8–10]. Our
observations show that the interaction between lidocaine
and ritonavir or cobicistat is not of clinical relevance for
this specific patient group and lidocaine may be used
safely in the treatment of syphilis with benzylpenicillin
benzathine. However, if higher doses of lidocaine are
administrated, this interaction may become relevant,
especially as pharmacokinetic modelling indicates that
inhibition of CYP3A4 may result in an increased half-life.
In these cases, use of lidocaine should be avoided or
lidocaine drug concentrations should be monitored,
especially in old patients or patients treated with drugs
known to affect hepatic blood flow or metabolism [10].
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(kg) cART Other medication T (min)
Peak (lidocaine)
(mg/l)
1 52 90.7 Ritonavir 100 mg qd
Emtricitabine 200 mg bid
Tenofovir 245 mg bid
Darunavir 800 mg qd
Beclomethasone nasal spray 50mg qd 31 0.2
2 53 93.5 Cobicistat 150 mg qd
Elvitegravir 150 mg qd
Emtricitabine 200 mg qd
Tenofoviralafenamide 10 mg qd
Acenocoumarol on basis of INR
Calcium carbonate 1.25 g qd
Cholecalciferol 800 IU qd
56 0.5
3 59 78 Ritonavir 100 mg bid
Darunavir 600 mg bid
Emtricitabine 200 mg qd
Tenofovir 245 mg qd
Etravirine 200 mg bid
None reported 32 0.6
cART, combination antiretroviral therapy; INR, international normalized ratio; IU, international units; T, time after administration.
University Medical Center Groningen, University of
Groningen, Hanzeplein 1, 9713 GZ Groningen, The
Netherlands.
Tel: +31 50 3619434; fax: +31 50 3614087;
e-mail: b.g.j.dekkers@umcg.nl
Received: 14 January 2019; accepted: 19 January
2019.
References
1. Antonio MB, Cuba GT, Vasconcelos RP, Alves APPS, da Silva
BO, Avelino-Silva VI. Natural experiment of syphilis treatment
with doxycycline or benzathine penicillin in HIV-infected
patients. AIDS 2018; 33:1.
2. Hook EW. Syphilis. Lancet 2017; 389:1550–1557.
3. Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potocˇnik M,
et al. 2014 European guideline on the management of syphilis.
J Eur Acad Dermatology Venereol 2014; 28:1581–1593.
4. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine
metabolism in human liver microsomes by cytochrome
P450IIIA4. Clin Pharmacol Ther 1989; 46:521–527.
5. Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ. Cobicistat versus
ritonavir: similar pharmacokinetic enhancers but some impor-
tant differences. Ann Pharmacother 2017; 51:1008–1022.
6. Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions
of clinical significance. Drug Saf 2000; 23:509–532.
7. Centini F, Fiore C, Riezzo I, Rossi G, Fineschi V. Suicide due to
oral ingestion of lidocaine: a case report and review of the
literature. Forensic Sci Int 2007; 171:57–62.
8. Cohen LS, Rosenthal JE, Horner DW, Atkins JM, Matthews OA,
Sarnoff SJ. Plasma levels of lidocaine after intramuscular ad-
ministration. Am J Cardiol 1972; 29:520–523.
9. DRUGDEX1 System. Lidocaine. Thomson Micromedex,
Greenwood Village, Color. [Accessed December 2018]
10. Campbell TJ, Williams KM. Therapeutic drug monitoring:
antiarrhythmic drugs. Br J Clin Pharmacol 2001; 52 (Suppl 1):
21S–34S.
DOI:10.1097/QAD.0000000000002162
Correspondence: behavioural changes following HIV seroconversion during the historical expansion of HIV
treatment in the United States
We read with great interest the article published by Zhu
et al. [1]. The authors have addressed an important
question regarding sexual behaviour in the context of
advances in HIV treatment. In their article, the authors
report that prior to the availability of HAART, the odds of
subsequent engagement in sex with at least two partners,
among MSM, decreased after seroconversion. Serocon-
version after the widespread availability of HAART was
associated with further reduced odds in engaging in these
sexual behaviours. These findings challenge the current
discussions regarding the association between HIV
treatment advances and sexual behaviour. The study
drew on data from 4616 MSM collected between 1984
and 2008, comparing men who seroconverted prior to
the availability of HAART and after. Given the design of
their study, it is still unclear whether the findings are
associated with availability of antiretroviral therapy or the
temporal trends in sexual behaviour in the United States
over this time period [2].
In 2012, the Food and Drug Administration (FDA)
approved emtricitabine/tenofovir for reducing the risk
of HIV transmission through sexual activity. Since then,
discussions have emerged regarding whether widespread
use of emtricitabine/tenofovir as preexposure prophy-
laxis (PrEP) contributes to riskier sexual behaviour
among populations already at a high risk of acquiring
HIV, a concept termed ‘risk compensation’ [3]. On the
basis of this concept, people taking PrEP or HIV
treatment would perceive a reduced risk of acquiring or
transmitting HIV and thus will engage in riskier sexual
behaviour; however, the authors have shown that for
HIV treatment, this reasoning is not applicable in the
cohort studied.
Qualitative research exploring the complexities of risk-
taking has begun to describe the diverse ways in which
PrEP influences sexual-wellbeing from the perspective of
MSM [4]. From the limited research that exists, the
perceived impacts of PrEP on sexual behaviour vary and
may in fact fluctuate over the course of one’s life. Hence,
it would be valuable to re-examine the cohort described
by Zhu et al. [1] for changes in sexual behaviour in the
current context of treatment as prevention [5] and PrEP
availability. Although limitations of the study constrain
the conclusions that can be drawn to MSM, if the authors
have access to data from the cohort after 2012, it would be
worthwhile to examine and comment on whether sexual
behaviours among this cohort have changed since the
availability of PrEP. Furthering our understanding of how
treatment as prevention and PrEP alter sexual behaviour
could aid in directing HIV policy and future research.
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